Misdiagnosis due to the Hook Effect in Prolactin Assay

Serkan Yener a Abdurrahman Comlekci a Nuri Arda b Suleyman Men c Sena Yesil a

a Department of Internal Medicine, Division of Endocrinology and Metabolism, and Departments of
b Neurosurgery and c Radiology, School of Medicine, Dokuz Eylul University, Izmir, Turkey

Introduction

Prolactinomas represent the most common type of secretory pituitary adenomas with a prevalence as high as 50% in some series [1]. Macroprolactinomas (≥ 1 cm) frequently present with serum prolactin levels in excess of 200 ng/ml. Mild or moderate hyperprolactinemia may occur due to stalk compression by nonsecretory pituitary tumors or sellar lesions. In giant prolactinomas (>4 cm in diameter or >4 cm of suprasellar extension) the prolactin levels usually correlate with tumor size and the elevations observed in prolactin levels are distinct [1].

Despite the accuracy and specificity of immunoradiometric assay, enzyme immunoassay or immunochromoluminometric assays used for prolactin, high antigen levels may impair antigen-antibody binding known as ‘hook effect’ that results in serious underestimation of prolactin [2].

In this report we describe a patient presenting with a giant pituitary adenoma in which dilution testing of serum prolactin levels confirmed the presence of the hook effect; we also review the clinical characteristics of 17 similar patients that were reported previously in the literature. For this purpose a Pubmed (Medline) search was conducted with the following keywords: ‘prolactin’ and...
'hook effect'. Ten published reports on 17 patients were found. These findings are presented as a background to the patient reported here.

**Case Report**

A 45-year-old woman with enlargement of her pituitary tumor was referred to the Department of Internal Medicine, School of Medicine, Dokuz Eylul University, Izmir, Turkey, from a secondary health center. She had a medical history including 4 previous pituitary surgeries (transsphenoidal and transcranial) and pituitary irradiation (cumulative dose of 4,000 Gy after the first operation) in the previous 20 years. The pathological diagnosis of the tumor was missing. The patient reported that she had suffered from galactorrhea and blurring of vision before the first operation and she also stated that laboratory investigations including prolactin measurements had always been within the normal range. She had not been treated with dopamine agonists. During follow-up, surgeries had been performed because of the enlargement of the pituitary tumor.

On admission the patient was suffering from headache and visual disturbances. She did not have galactorrhea or breast tenderness. She had total loss of vision in the left eye since a previous operation. She had secondary amenorrhea and central diabetes insipidus. She was on phenytoin (300 mg/day) and desmopressin acetate-DDAVP (20 µg/day intranasally). The patient had no medical history of any other diseases. Her blood pressure was 110/70 mm Hg and pulse rate was 72/min. Physical examination revealed the presence of left amaurosis and lateral hemianopsia in the right eye. The light reflex was absent in the left eye and ophthalmologic examination showed optic atrophy. Right eye movements were normal. Deep tendon reflexes were normal and there was no pathological reflex.

Cranial magnetic resonance imaging (MRI) revealed the presence of a large and invasive tumor at the sella, its greatest diameter being 50 mm. The mass invaded the optic chiasma, extending to the pontocerebellar region, left cavernous sinus and bilateral suprachiasmoid regions. Laboratory testing of serum demonstrated moderate hyperprolactinemia, prolactin 164.5 ng/ml (reference range: 1.9–25.0 ng/ml), secondary hypothyroidism, FT3 10.93 pmol/l (reference range: 10.29–24.45 pmol/l), TSH 0.57 mU/l (reference range: 0.4–5.0 mU/l), secondary hypogonadism, estradiol <10 pmol/l (reference range: 73–550 pmol/l), FSH 1.33 IU/l (reference range: 4–13 IU/l), LH 0.25 IU/l (reference range: 1.68–15.0 IU/l) and secondary adrenal insufficiency, 8:00 a.m. cortisol 29.79 nmol/l (reference range: 140–690 nmol/l), ACTH <10 pg/ml (reference range: 9–52 pg/ml). Renal function, liver function, serum electrolytes and urine density were all within the reference range. Glucocorticoid replacement was started with prednisolone 15 mg/day postoperatively. Because of the discrepancy between the serum prolactin level and the size of the pituitary mass, serum samples were retested for prolactin after 1/100 dilution. This gave a serum prolactin level of 14,640 ng/ml. The patient was given the dopamine agonist cabergoline 3 mg/week. Levothyroxine 50 µg/day was initiated in the second week of glucocorticoid therapy and prednisolone dose was gradually tapered to 7.5 mg/day. Six weeks after the initiation of cabergoline the prolactin levels decreased to 3,660 ng/ml. In the 24th week of therapy the prolactin level was 1.2 ng/ml and the size of the pituitary mass was stable as seen in MRI. The prolactin level was 1.5 ng/ml in the first year of therapy and MRI findings were consistent with mild regression of the tumor mass observed in the coronal T1-weighted gadolinium-enhanced MRI scan. The patient is being followed with cabergoline 3 mg/week, prednisolone 5 mg/day, levothyroxine 50 µg/day and desmopressin acetate-DDAVP (20 µg/day intranasally).

**Discussion**

An accurate prolactin measurement is essential for the differential diagnosis of pituitary tumors as false-negative results lead to surgical procedures or pituitary irradiation with serious morbidities. There are previous reports of patients with giant pituitary tumors showing mild or moderately elevated prolactin levels because of the hook effect [2–11].

A review of the literature on giant prolactinomas and the hook effect showed 11 reports of 18 patients, including our present report (table 1). Male dominance is manifest (83.3%) and the mean age of patients is 38.5 years. The symptoms of hyperprolactinemia in men (usually impotence and infertility) are obscure when compared to women and this may lead to the delayed recognition and consequently existence of larger tumors [1].

The mean prolactin level of patients before dilution was 106 ng/ml. This level is considered to be a gray area in the management of pituitary macroadenomas as the

---

**Table 1. Characteristics of patients with macroprolactinoma and the hook effect**

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Patients reported in the literature [2–11]</th>
<th>Patient in this report</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender, female/male</td>
<td>3/15</td>
<td>female</td>
</tr>
<tr>
<td>Mean age, years</td>
<td>38.5 (24–65)</td>
<td>45</td>
</tr>
<tr>
<td>Prolactin level before dilution, ng/ml</td>
<td>106 (31–212)</td>
<td>164</td>
</tr>
<tr>
<td>Prolactin level after dilution, ng/ml</td>
<td>48,386 (2,222–280,000)</td>
<td>14,640</td>
</tr>
<tr>
<td>Average difference in prolactin value from dilution, ng/ml</td>
<td>35,503 (2,167–279,969)</td>
<td>14,534</td>
</tr>
<tr>
<td>FSH-LH deficiency</td>
<td>13/17</td>
<td>yes</td>
</tr>
<tr>
<td>Galactorrhea</td>
<td>1/17</td>
<td>no</td>
</tr>
<tr>
<td>Visual disturbance</td>
<td>16/17</td>
<td>yes</td>
</tr>
<tr>
<td>ACTH deficiency</td>
<td>4/17</td>
<td>yes</td>
</tr>
<tr>
<td>TSH deficiency</td>
<td>6/17</td>
<td>yes</td>
</tr>
<tr>
<td>Preoperative diagnosis</td>
<td>9/17</td>
<td>no</td>
</tr>
</tbody>
</table>

ACTH = Adrenocorticotropin hormone; FSH = follicle-stimulating hormone; LH = luteinizing hormone; TSH = thyroid-stimulating hormone.
differentiation of stalk compression by a nonfunctional macroadenoma from a macroprolactinoma cannot easily be done with this moderately elevated prolactin level.

Galactorrhea was present in 2/18 (11.1%). The male dominance of the patient group probably explained the low incidence of galactorrhea. Visual disturbance is one of the major complaints of patients on admission. Hypogonadism is a frequent manifestation of hyperprolactinemia. In this particular patient population hypogonadotropic hypogonadism is prominent (the rate of FSH-LH deficiency is 77%) because of the compression of a giant tumor on pituitary cells. The secondary adrenocortical deficiency rate in this patient group is 27.8% and the secondary hypothyroidism rate is 38.9%. It is interesting to note that only 39% (7/18) of the patients could be diagnosed before the operation. We found that tumor size, age, gender or pre- and postdilution prolactin levels had no significant effects (p > 0.05) on the duration prior to diagnosis. All patients except 1 were treated with dopamine agonists and both prolactin levels and tumor size were demonstrated to decrease after initiation of therapy. These drugs normalize serum prolactin levels and can reduce the tumor size in most patients. Tumor shrinkage may not start for several months but it is a continuous process [1]. Significant reduction of the tumor mass in the present patient was achieved in the 1st year of therapy.

Conclusion

In patients presenting with mild or moderately high plasma prolactin levels, serum samples should be diluted before repeating the assay. This will help to distinguish a nonfunctional pituitary adenoma causing stalk compression from a prolactin-secreting tumor and to avoid unnecessary surgical procedures or pituitary irradiation.

References


